AU683836B2 - Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 - Google Patents

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 Download PDF

Info

Publication number: AU683836B2
Authority: AU; Australia
Prior art keywords: seq; amino acid; monoclonal antibody; chain variable; antibody
Prior art date: 1992-02-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU36560/93A

Other languages

English (en)

Other versions

AU3656093A (en

Inventor

John S. Abrams

Chuan-Chu Chou

Chung-Her Jenh

Nicholas J Murgolo

Mary E. Petro

Jon E Silver

Stephen Tindall

William T Windsor

Paul J Zavodny

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-06

Filing date

1993-02-04

Publication date

1997-11-27

1993-02-04 Application filed by Schering Corp filed Critical Schering Corp

1993-09-03 Publication of AU3656093A publication Critical patent/AU3656093A/en

1997-11-27 Application granted granted Critical

1997-11-27 Publication of AU683836B2 publication Critical patent/AU683836B2/en

2013-02-04 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AU36560/93A 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 Ceased AU683836B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83284292A	1992-02-06	1992-02-06
US832842		1992-02-06
PCT/US1993/000759 WO1993016184A1 (en)	1992-02-06	1993-02-04	Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Publications (2)

Publication Number	Publication Date
AU3656093A AU3656093A (en)	1993-09-03
AU683836B2 true AU683836B2 (en)	1997-11-27

Family

ID=25262763

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU36560/93A Ceased AU683836B2 (en)	1992-02-06	1993-02-04	Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Country Status (21)

Country	Link
US (1)	US6451982B1 (2)
EP (1)	EP0625201A1 (2)
JP (2)	JPH07505767A (2)
KR (2)	KR0150060B1 (2)
CN (1)	CN1077991A (2)
AR (1)	AR248044A1 (2)
AU (1)	AU683836B2 (2)
CA (1)	CA2129445A1 (2)
CZ (1)	CZ291039B6 (2)
FI (1)	FI943635L (2)
HU (1)	HUT67943A (2)
IL (1)	IL104620A (2)
NO (1)	NO942912L (2)
NZ (1)	NZ249633A (2)
PL (1)	PL176393B1 (2)
RU (1)	RU94045919A (2)
SG (1)	SG49597A1 (2)
SK (1)	SK280610B6 (2)
TN (1)	TNSN93012A1 (2)
WO (1)	WO1993016184A1 (2)
ZA (1)	ZA93779B (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG49597A1 (en)	1992-02-06	1998-06-15	Schering Corp	Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) *	1994-06-17	2007-04-03	Celltech R&D Limited	Interleukin-5 specific recombinant antibodies
US6056957A (en) *	1994-08-04	2000-05-02	Schering Corporation	Humanized monoclonal antibodies against human interleukin-5
WO1996021000A2 (en) *	1994-12-23	1996-07-11	Smithkline Beecham Corporation	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US7399837B2 (en)	1995-12-22	2008-07-15	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683983A (en) *	1995-06-07	1997-11-04	Glaxo Group Limited	Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) *	1995-06-07	1997-08-05	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) *	1995-06-07	1997-09-16	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) *	1995-06-07	1997-10-14	Glaxo Group Limited	Peptides and compounds that bind to the IL-5 receptor
CN1241944C (zh) *	1995-09-11	2006-02-15	协和发酵工业株式会社	抗人白介素－5受体α链的抗体
US6228360B1 (en) *	1998-08-19	2001-05-08	Ajinomoto Co., Inc.	Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en)	1999-12-16	2006-09-19	Affymax, Inc.	Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko)	2001-07-26	2004-10-20	메덱스젠 주식회사	연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2327830T3 (es) *	2002-03-29	2009-11-04	Schering Corporation	Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7927840B2 (en)	2006-09-11	2011-04-19	Gen Probe Incorporated	Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2868618C (en) *	2002-10-16	2017-05-23	Gen-Probe Incorporated	Compositions and methods for detecting west nile virus
CN100432105C (zh)	2002-12-17	2008-11-12	默克专利有限公司	与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
ITRM20030601A1 (it) *	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2585977C (en)	2004-10-28	2013-07-02	Kyowa Hakko Kogyo Co., Ltd.	Remedy for endometriosis
EP3072522B1 (en)	2005-01-06	2019-04-24	Novo Nordisk A/S	Anti-kir combination treatments and methods
EP2567976B1 (en)	2005-03-23	2017-07-19	Genmab A/S	Antibodies against CD38 for treatment of multiple myeloma
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2010526088A (ja)	2007-04-30	2010-07-29	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗ｉｌ−５抗体を投与するための方法
WO2009120927A2 (en)	2008-03-28	2009-10-01	Smithkline Beecham Corporation	Methods of treatment
US20110229903A1 (en) *	2008-10-23	2011-09-22	Ulrich Goepfert	Determination of immunoglobulin encoding nucleic acid
WO2012083370A1 (en) *	2010-12-22	2012-06-28	Cephalon Australia Pty Ltd	Modified antibody with improved half-life
WO2013087912A1 (en)	2011-12-16	2013-06-20	Synthon Biopharmaceuticals B.V.	Compounds and methods for treating inflammatory diseases
US9677018B2 (en)	2013-01-09	2017-06-13	Thyssenkrupp Industrial Solutions Ag	Process for the production of synthesis gas from hard coal
UA122670C2 (uk)	2014-09-08	2020-12-28	Сефалон, Інк.	Спосіб лікування еозинофільної астми у пацієнта
ES3053874T3 (en)	2015-08-24	2026-01-27	Glaxosmithkline Ip No 2 Ltd	Biopharmaceutical compositions
CA3064859A1 (en)	2017-06-06	2018-12-13	Glaxosmithkline Llc	Biopharmaceutical compositions and methods for pediatric patients
JP2019026625A (ja) *	2017-08-03	2019-02-21	日本全薬工業株式会社	抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en)	2017-08-24	2022-01-18	Cephalon, Inc.	Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
CN111065651B (zh) *	2017-09-29	2023-07-14	江苏恒瑞医药股份有限公司	Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) *	2017-12-21	2019-06-28	三生国健药业（上海）股份有限公司	结合人il-5的单克隆抗体、其制备方法和用途
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5096704A (en)	1988-11-03	1992-03-17	Schering Corporation	Method of treating eosinophilia
ZA898322B (en) *	1988-11-03	1990-11-28	Schering Corp	Method of preventing or reducing eosinophilia
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CA2041271A1 (en) *	1990-04-30	1991-10-31	Bradford A. Jameson	Peptide analogs to proteins of the immunoglobin superfamily
SG49597A1 (en)	1992-02-06	1998-06-15	Schering Corp	Design cloning and expression of humanized monoclonal antibodies against human interleukin-5

1993
- 1993-02-04 SG SG1996000571A patent/SG49597A1/en unknown
- 1993-02-04 SK SK918-94A patent/SK280610B6/sk unknown
- 1993-02-04 RU RU94045919/13A patent/RU94045919A/ru unknown
- 1993-02-04 CZ CZ19941910A patent/CZ291039B6/cs not_active IP Right Cessation
- 1993-02-04 WO PCT/US1993/000759 patent/WO1993016184A1/en not_active Ceased
- 1993-02-04 FI FI943635A patent/FI943635L/fi unknown
- 1993-02-04 KR KR1019940702711A patent/KR0150060B1/ko not_active Expired - Fee Related
- 1993-02-04 AR AR93324239A patent/AR248044A1/es active
- 1993-02-04 HU HU9402293A patent/HUT67943A/hu unknown
- 1993-02-04 NZ NZ249633A patent/NZ249633A/en unknown
- 1993-02-04 ZA ZA93779A patent/ZA93779B/xx unknown
- 1993-02-04 AU AU36560/93A patent/AU683836B2/en not_active Ceased
- 1993-02-04 PL PL93304715A patent/PL176393B1/pl unknown
- 1993-02-04 JP JP5514104A patent/JPH07505767A/ja active Pending
- 1993-02-04 EP EP93905764A patent/EP0625201A1/en not_active Withdrawn
- 1993-02-04 CA CA002129445A patent/CA2129445A1/en not_active Abandoned
- 1993-02-04 IL IL10462093A patent/IL104620A/xx not_active IP Right Cessation
- 1993-02-05 CN CN93102685A patent/CN1077991A/zh active Pending
- 1993-02-05 TN TNTNSN93012A patent/TNSN93012A1/fr unknown
1994
- 1994-08-05 NO NO942912A patent/NO942912L/no not_active Application Discontinuation
- 1994-08-06 KR KR1019940702711A patent/KR950700413A/ko active Granted
1999
- 1999-11-11 JP JP11321698A patent/JP2000210097A/ja active Pending
2000
- 2000-03-28 US US09/537,911 patent/US6451982B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FI943635A7 (fi)	1994-08-05
KR0150060B1 (ko)	1998-08-17
FI943635A0 (fi)	1994-08-05
IL104620A0 (en)	1993-06-10
CZ191094A3 (en)	1994-12-15
NO942912L (no)	1994-10-06
CN1077991A (zh)	1993-11-03
JPH07505767A (ja)	1995-06-29
HU9402293D0 (en)	1994-10-28
SG49597A1 (en)	1998-06-15
JP2000210097A (ja)	2000-08-02
PL176393B1 (pl)	1999-05-31
WO1993016184A1 (en)	1993-08-19
RU94045919A (ru)	1996-11-10
ZA93779B (en)	1993-08-05
FI943635L (fi)	1994-08-05
AR248044A1 (es)	1995-05-31
SK91894A3 (en)	1995-02-08
KR950700413A (ko)	1995-01-16
CZ291039B6 (cs)	2002-12-11
NO942912D0 (2)	1994-08-05
HUT67943A (en)	1995-05-29
US6451982B1 (en)	2002-09-17
TNSN93012A1 (fr)	1994-03-17
IL104620A (en)	2000-02-29
EP0625201A1 (en)	1994-11-23
SK280610B6 (sk)	2000-05-16
CA2129445A1 (en)	1993-08-07
AU3656093A (en)	1993-09-03
NZ249633A (en)	1995-12-21

Legal Events

Date	Code	Title	Description
2003-09-04	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
AU683836B2 (en)	1997-11-27	Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
US5863537A (en)	1999-01-26	Humanized monoclonal antibodies against human interleukin-4
US5705154A (en)	1998-01-06	Humanized monoclonal antibodies against human interleukin-4
US6056957A (en)	2000-05-02	Humanized monoclonal antibodies against human interleukin-5
JP3946256B2 (ja)	2007-07-18	ヒトインターロイキン５受容体α鎖に対する抗体
JP5177444B2 (ja)	2013-04-03	Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
JP2008029355A (ja)	2008-02-14	Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
RS55788B1 (sr)	2017-08-31	Inženjerisana anti-il-23 antitela
US5597710A (en)	1997-01-28	Humanized monoclonal antibodies against human interleukin-4
JPH0630788A (ja)	1994-02-08	ヒトインターロイキン−１に対する組換え抗体
JP2843674B2 (ja)	1999-01-06	ヒトインターロイキン−４に対するヒト化モノクローナル抗体のクローニング及び発現
KR102903323B1 (ko)	2025-12-23	고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
HK40057229A (en)	2022-04-08	Anti-il-17a antibody and use thereof
HK1008831B (en)	2000-03-24	Cloning and expression of humanized monoclonal antibodies against human interleukin-4